PT - JOURNAL ARTICLE AU - Rovida, Francesca AU - Cassaniti, Irene AU - Paolucci, Stefania AU - Percivalle, Elena AU - Sarasini, Antonella AU - Piralla, Antonio AU - Giardina, Federica AU - Sammartino, Jose Camilla AU - Ferrari, Alessandro AU - Bergami, Federica AU - Muzzi, Alba AU - Novelli, Viola AU - Meloni, Alessandro AU - Grugnetti, Anna Maria AU - Grugnetti, Giuseppina AU - Rona, Claudia AU - Daglio, Marinella AU - Marena, Carlo AU - Triarico, Antonio AU - Lilleri, Daniele AU - Baldanti, Fausto TI - SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted AID - 10.1101/2021.06.29.21259500 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.29.21259500 4099 - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259500.short 4100 - http://medrxiv.org/content/early/2021/07/03/2021.06.29.21259500.full AB - Vaccine breakthrough SARS-CoV-2 infection was monitored in 3694 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV2 infection was detected in 33 subjects, with a 3-months cumulative incidence of 0.90% and 0.42% in SARS-CoV-2-naïve and experienced subjects, respectively. Vaccine protection was 87% in naïve and 94% in experienced subjects when compared with a pre-vaccination control group. The infection was mildly symptomatic in 16 (48%) and asymptomatic in 17 (52%) subjects. Virus isolation was positive in 7/13 (54%) symptomatic and 4/8 (50%) asymptomatic subjects tested, and B.1.1.7 lineage was detected in all subjects. Antibody and T-cell responses were not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, was observed in two (6.1%) cases.This real-world data confirm the protective effect of BNT162b2 vaccine. A triple antigenic exposure, as occurring in experienced subjects, may confer a higher protection. Virus transmission from vaccinated subjects is infrequent.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Fondazione Cariplo [grant CoVIM, no. 2020-1374] and Ministero della Salute, Ricerca Finalizzata [grants no. COVID-2020-12371760 and COVID-2020-12371817]. AP and FB have received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 101003650.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study procedures were approved by Fondazione IRCCS Policlinico San Matteo. Ethics approval was provided by "Comitato Etico Area Pavia" (Procedures no. 20200101361 and 2021000232).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.